The New England journal of medicine, 2020-12, Vol.383 (23), p.2207-2218
- André, Thierry
- Shiu, Kai-Keen
- Kim, Tae Won
- Jensen, Benny Vittrup
- Jensen, Lars Henrik
- Punt, Cornelis
- Smith, Denis
- Garcia-Carbonero, Rocio
- Benavides, Manuel
- Gibbs, Peter
- de la Fouchardiere, Christelle
- Rivera, Fernando
- Elez, Elena
- Bendell, Johanna
- Le, Dung T
- Yoshino, Takayuki
- Van Cutsem, Eric
- Yang, Ping
- Farooqui, Mohammed Z.H
- Marinello, Patricia
- Diaz, Luis A
2020
Details
- Autor(en) / Beteiligte
- André, Thierry
- Shiu, Kai-Keen
- Kim, Tae Won
- Jensen, Benny Vittrup
- Jensen, Lars Henrik
- Punt, Cornelis
- Smith, Denis
- Garcia-Carbonero, Rocio
- Benavides, Manuel
- Gibbs, Peter
- de la Fouchardiere, Christelle
- Rivera, Fernando
- Elez, Elena
- Bendell, Johanna
- Le, Dung T
- Yoshino, Takayuki
- Van Cutsem, Eric
- Yang, Ping
- Farooqui, Mohammed Z.H
- Marinello, Patricia
- Diaz, Luis A
- Titel
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- Ist Teil von
- The New England journal of medicine, 2020-12, Vol.383 (23), p.2207-2218
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- Elektronische Zeitschriftenbibliothek (Open access)
- Beschreibungen/Notizen
- Colorectal cancer is genetically heterogeneous. Tumors in some patients have defects in mismatch DNA repair. These tumors have a high level of mutations that can lead to immune recognition. In a group of patients with microsatellite-unstable tumors, pembrolizumab led to longer progression-free survival and was less toxic than standard chemotherapy.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2017699Titel-ID: cdi_proquest_journals_2466344814
- Format
- –
- Schlagworte
- 5-Fluorouracil, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Antineoplastic Agents, Immunological - adverse effects, Antineoplastic Agents, Immunological - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Bevacizumab, Biomarkers, Tumor - genetics, Brain Neoplasms, Cancer, Cancer therapies, Chemotherapy, Colorectal cancer, Colorectal carcinoma, Colorectal Neoplasms - drug therapy, Colorectal Neoplasms - genetics, Colorectal Neoplasms - mortality, Drug therapy, Female, Fluorouracil - therapeutic use, Genetic aspects, Growth factors, Health aspects, Humans, Immune Checkpoint Inhibitors - adverse effects, Immune Checkpoint Inhibitors - therapeutic use, Immunotherapy, Kaplan-Meier Estimate, Life Sciences, Male, Metastases, Metastasis, Microsatellite Instability, Middle Aged, Monoclonal antibodies, Mutation, Neoplastic Syndromes, Hereditary, Patient outcomes, Patient safety, Patients, PD-1 protein, Pembrolizumab, Progression-Free Survival, Solid tumors, Survival, Targeted cancer therapy, Tumors